Adenoviral vectors for gene therapy

被引:141
作者
Douglas, Joanne T.
机构
[1] Univ Alabama, Dept Med, Div Human Gene Therapy, Birmingham, AL 35294 USA
[2] Univ Alabama, Dept Obstet & Gynecol, Div Human Gene Therapy, Birmingham, AL 35294 USA
[3] Univ Alabama, Dept Pathol, Div Human Gene Therapy, Birmingham, AL 35294 USA
[4] Univ Alabama, Dept Surg, Div Human Gene Therapy, Birmingham, AL 35294 USA
[5] Univ Alabama, Gene Therapy Ctr, Birmingham, AL 35294 USA
关键词
D O I
10.1007/s12033-007-0021-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vectors based on human adenovirus serotypes 2 (Ad2) and 5 (Ad5) of species C possess a number of features that have favored their widespread employment for gene delivery both in vitro and in vivo. However, the use of recombinant Ad2- and Ad5-based vectors for gene therapy also suffers from a number of disadvantages. These vectors possess the tropism of the parental viruses, which infect all cells that possess the appropriate surface receptors, precluding the targeting of specific cell types. Conversely, some cell types that represent important targets for gene transfer express only low levels of the cellular receptors, which lead to inefficient infection. Another major disadvantage of Ad2- and Ad5-based vectors in vivo is the elicitation of both an innate and an acquired immune response. Considerable attention has therefore been focused on strategies to overcome these limitations, thereby permitting the full potential of adenoviral vectors to be realized.
引用
收藏
页码:71 / 80
页数:10
相关论文
共 64 条
[41]   POLYPEPTIDES OF ADENOVIRUS .I. EVIDENCE FOR MULTIPLE PROTEIN COMPONENTS IN VIRION AND A COMPARISON OF TYPES 2 7A AND 12 [J].
MAIZEL, JV ;
WHITE, DO ;
SCHARFF, MD .
VIROLOGY, 1968, 36 (01) :115-+
[42]   A SIMPLE TECHNIQUE FOR THE RESCUE OF EARLY REGION-I MUTATIONS INTO INFECTIOUS HUMAN ADENOVIRUS TYPE-5 [J].
MCGRORY, WJ ;
BAUTISTA, DS ;
GRAHAM, FL .
VIROLOGY, 1988, 163 (02) :614-617
[43]  
Miller CR, 1998, CANCER RES, V58, P5738
[44]   Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy [J].
Mittereder, N ;
March, KL ;
Trapnell, BC .
JOURNAL OF VIROLOGY, 1996, 70 (11) :7498-7509
[45]   Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes [J].
Mizuguchi, H ;
Hayakawa, T .
GENE, 2002, 285 (1-2) :69-77
[46]   Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells [J].
Nalbantoglu, J ;
Pari, G ;
Karpati, G ;
Holland, PC .
HUMAN GENE THERAPY, 1999, 10 (06) :1009-1019
[47]   Current status of gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers [J].
Peng, ZH .
HUMAN GENE THERAPY, 2005, 16 (09) :1016-1027
[48]   Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery [J].
Plog, Malinda S. ;
Guyre, Cheryl A. ;
Roberts, Bruce L. ;
Goldberg, Mark ;
George, Judith A. St. ;
Perricone, Michael A. .
HUMAN GENE THERAPY, 2006, 17 (07) :705-716
[49]   Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity [J].
Roberts, DM ;
Nanda, A ;
Havenga, MJE ;
Abbink, P ;
Lynch, DM ;
Ewald, BA ;
Liu, J ;
Thorner, AR ;
Swanson, PE ;
Gorgone, DA ;
Lifton, MA ;
Lemckert, AAC ;
Holterman, L ;
Chen, B ;
Dilraj, A ;
Carville, A ;
Mansfield, KG ;
Goudsmit, J ;
Barouch, DH .
NATURE, 2006, 441 (7090) :239-243
[50]   Adenovirus p53 gene therapy [J].
Roth, JA .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2006, 6 (01) :55-61